Verquvo, a new drug for heart failure, aims to enter insurance benefits. dksl According to related industries, Bayer Korea has submitted an application for payment of Verquvo, a water-soluble guanylate cyclase (sGC) promoter that promotes the synthesis of intracellular cyclic Guanosine (cGMP). Verquvo was recently approved in December last year as a combination therapy to reduce the risk of death from cardiovascular disease and hospitalization due to heart failure in patients with symptomatic chronic heart failure, whose left ventricular ejection rate, which experienced intravenous diuretic administration, has decreased to less than 45%. Existing heart failure treatments have been a method of blocking harmful effects